Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Sep 19;2(6):317-321.
doi: 10.1002/jgh3.12091. eCollection 2018 Dec.

Resolution of ascites and hepatic encephalopathy and absence of variceal bleeding in decompensated hepatitis C virus cirrhosis patients

John Romano  1 , Omar T Sims  2   3   4   5 , Joshua Richman  6 , Yuqi Guo  7 , Tasnia Matin  8 , Mohamed Shoreibah  9 , Vishnu Kommineni  1 , Krishna Venkata  1 , Omar I Massoud  9
Affiliations

Resolution of ascites and hepatic encephalopathy and absence of variceal bleeding in decompensated hepatitis C virus cirrhosis patients

John Romano et al. JGH Open. .

Abstract

Background and aims: The aims of this study were to examine changes in the proportion of decompensated hepatitis C virus (HCV) cirrhosis patients with ascites, hepatic encephalopathy, and variceal bleeding at pretreatment compared to 3 and 12 months post-sustained virological response (SVR) and to compare pretreatment and post-SVR model of end-stage liver disease and Child-Pugh scores and alpha-fetoprotein levels.

Methods: Electronic medical records of 64 decompensated HCV cirrhosis patients who received direct-acting antivirals were reviewed. The McNemar-Bowker test and the Wilcoxon-Signed Rank test were used to compare patient outcomes.

Results: Ascites was resolved in 29% of patients 3 months post-SVR (65% vs 36%, P < 0.01) and in 35% of patients 12 months post-SVR (65% vs 30%, P = 0.07). Hepatic encephalopathy was resolved in 54% of patients 3 months post-SVR (70% vs 16%, P < 0.01) and in 48% of patients 12 months post-SVR (70% vs 22% P = 0.03). Variceal bleeding was absent in 32% of patients 3 months post-SVR (35% vs 3%, P < 0.01) and in 27% of patients 12 months post-SVR (35% vs 8%, P < 0.01). Alpha-fetoprotein levels were significantly reduced post-SVR, but model of end-stage liver disease and Child-Pugh scores were not.

Conclusions: Decompensated HCV cirrhosis patients who achieved SVR with direct-acting antiviral treatment had significant reductions in manifestations of hepatic decompensation sustainable up to 1 year post-SVR.

Keywords: decompensated cirrhosis; direct acting antivirals; hepatitis C; treatment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Change in the manifestations of decompensated cirrhosis prior to and post‐treatment with direct‐acting antiviral. formula image, HE; formula image Ascites; formula image, VB.
Figure 2
Figure 2
Change in AFP level prior to and post‐treatment with direct‐acting antiviral.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Gower E, Estes C, Blach S, Razavi‐Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J. Hepatol. 2014; 61: S45–57. - PubMed
    1. Dore GJ, Ward J, Thursz M. Hepatitis C disease burden and strategies to manage the burden (Guest Editors Mark Thursz, Gregory Dore and John Ward). J. Viral Hepat. 2014; 21: 1–4. - PubMed
    1. Lim S, Vos T, Flaxman A et al A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380: 2224–60. - PMC - PubMed
    1. Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age‐specific antibody to HCV seroprevalence. Hepatology. 2013; 57: 1333–42. - PubMed
    1. Davis GL, Alter MJ, El‐Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)‐infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010; 138: 513–21. - PubMed

LinkOut - more resources